What the research shows, and what it means for you
By Dr. David LaMond, Medical Director Blue Sky MD
If a family member has had breast cancer, you’ve probably wondered whether hormone therapy is even on the table for you.
Here’s the short answer: family history alone does not automatically rule out hormone therapy.
What matters is your personal risk, your specific hormone regimen, and—if you’ve had breast cancer yourself—a separate, carefully individualized conversation. Let’s walk through what the research shows, because a lot of what patients hear about “hormones and breast cancer” is oversimplified, outdated, or just wrong.
Family History Alone Doesn’t Rule Out Hormone Therapy
A mother, sister, or aunt with breast cancer raises your baseline risk—that part is true. But raising your baseline risk is not the same thing as making hormone therapy unsafe for you. In my practice, the question I’m answering isn’t “is HRT safe or unsafe”, it’s “what is this specific patient’s absolute risk, and does that change with this specific regimen, for this length of time, with this level of breast surveillance in place?” Those are very different questions, and they lead to very different conversations than a blanket yes-or-no.
If you have a family history but no personal history of breast cancer and no known genetic mutation in the family, hormone therapy is not automatically off the table. What we do instead is look at the whole picture: whether you still have your uterus, your age and how long it’s been since menopause, your mammogram results and breast density, any prior biopsies, and lifestyle factors like alcohol use and activity level. Then we make the decision together.
What the Landmark Women’s Health Initiative Study Actually Found
Almost everything you’ve heard about “hormones causing breast cancer” traces back to one study: the Women’s Health Initiative (WHI), a large, randomized trial from the early 2000s. But the actual findings are more nuanced than the headlines that followed them.
Estrogen alone (for women without a uterus)
In the arm of the study where women without a uterus took estrogen by itself, breast cancer rates were lower than in women taking a placebo, and that held up over long-term follow-up. That doesn’t make estrogen a cancer-prevention drug, but it’s a far cry from the fear most people carry around.
Estrogen plus a progestin (for women with a uterus)
In women who still had a uterus and took estrogen combined with a synthetic progestin, breast cancer rates did increase. This is the finding that shaped most of the public narrative. But it’s specific to that regimen, and it doesn’t mean every form of combined hormone therapy carries the same risk. The type of progesterone matters. Micronized (bioidentical) progesterone has a more favorable safety profile in observational research than the synthetic progestin used in the WHI trial.
The bottom line: “hormones cause breast cancer” is not an accurate summary of the data. “Risk depends on which hormones, in what form, for how long, and in whom” is a much more honest one.
When Should You Consider Genetic Testing?
Not every family history needs a genetics referral, but some patterns should prompt one.
I recommend formal genetic counseling when the family history includes any of the following: a known pathogenic gene variant in a relative, ovarian or fallopian tube cancer anywhere in the family, male breast cancer, breast cancer diagnosed at 50 or younger, bilateral breast cancer, multiple close relatives affected on the same side of the family, or a pattern that mixes breast cancer with ovarian, pancreatic, or aggressive prostate cancer.
One detail that surprises a lot of patients: whenever possible, we try to test the affected relative first (the person who had cancer) rather than starting with you. Their result is far more informative and tells us much more clearly what your own risk looks like.
Understanding Your Genetic Test Results
Genetic test results aren’t simply “good news” or “bad news.” There are really four possible outcomes, and each one means something different:
- Pathogenic or likely pathogenic variant: means a disease-linked mutation was found. This is the one result that clearly changes the plan: referral to genetics or a high-risk breast program, and a much more individualized approach to screening and hormone therapy.
- True negative: means you tested negative for the exact mutation already known to run in your family. This is genuinely reassuring because it means your risk from that mutation returns close to the general population level.
- Uninformative negative: means no mutation was found, but no mutation was known in your family to begin with, or the pattern still isn’t explained. This is not the same as a true negative. Your family history still matters and should still guide your screening.
- Variant of uncertain significance (VUS): Indicates a genetic difference was found, but we don’t yet know if it causes disease. A VUS should not change your hormone therapy, your imaging, or any surgical decisions. We manage you by your personal and family history while the lab continues to study that variant.
If your doctor orders genetic testing, ask directly which of these four outcomes you got. The label matters as much as the test itself.
Have You Had Breast Cancer? Hormone Therapy May Still Be an Option
If you have a personal history of breast cancer, this is a genuinely different conversation from family history alone, and it deserves to be treated that way.
As a rule, systemic estrogen-containing hormone therapy is avoided after breast cancer, especially hormone-receptor-positive disease, unless it’s being coordinated directly with your oncology team.
But “no systemic estrogen” doesn’t mean “no hormone therapy is ever appropriate again.” This is where testosterone-based therapy enters the conversation, and it’s treated as its own distinct pathway, not a workaround for estrogen.
Testosterone Pellet Therapy for Breast Cancer Survivors: What the Research Shows
This is a topic I feel strongly about, because the data is more reassuring than most patients realize—and honestly, most physicians, too.
In a ten-year prospective study following 1,267 pre- and postmenopausal women on testosterone or testosterone/anastrozole pellet therapy, researchers observed 11 invasive breast cancers where 18 would have been expected based on population rates—about 39% lower than expected. A follow-up study extending the data to fifteen years found a similar pattern: roughly 47% lower incidence than expected. In a separate study focused specifically on breast cancer survivors, 72 women with stage 0 through stage 4 disease were treated with testosterone plus anastrozole (a medication that blocks estrogen conversion), and no recurrences were reported through up to eight years of follow-up.
To be clear about what this evidence can and cannot say: these are observational studies, not randomized trials, and they don’t prove that testosterone prevents breast cancer. What they do show is a consistent, reassuring safety signal across nearly two decades of research, which is exactly why this is an area worth understanding rather than avoiding out of caution alone.
In my own practice, I’ve personally used testosterone pellet therapy in breast cancer survivors for well over a decade, and it’s become a standard part of how we care for these patients at Blue Sky MD. It’s always implemented in tandem with oncology coordination, the lowest effective dose, and close monitoring of hormone levels, symptoms, and breast surveillance.
How We Approach This at Blue Sky MD
Every recommendation starts with your specific history, not a generic protocol. That means asking real questions: Do you still have your uterus? How long has it been since menopause? What does your breast imaging show? Is there a personal or family history of breast or ovarian cancer? Has a genetic pattern already been identified?
From there, we build a plan together, one that’s honest about what the evidence supports, what it doesn’t, and where the uncertainty lies.
If you’re navigating a family history of breast cancer, a prior diagnosis yourself, or you’re simply unsure whether hormone therapy is safe for you, that’s exactly the conversation we’re here to have. You deserve a real answer, not a reflexive “no.”
If you’re interested in finding out if HRT is right for you or if you’d like to discuss your options, contact us to get started.
This article is for general education and isn’t a substitute for personalized medical advice. Every hormone therapy decision, especially with a personal or family history of breast cancer, should be made with your own physician, based on your complete health history.
Sources: Women’s Health Initiative randomized trials (JAMA 2020); Glaser RL et al., BMC Cancer 2019 and Adv Prev Med Health Care 2025 (testosterone implant cohorts); Glaser RL et al., J Clin Oncol 2014 (testosterone + anastrozole in breast cancer survivors); ACOG Committee Opinion No. 793; Davis SR et al., J Clin Endocrinol Metab 2019 (Global Consensus on Testosterone Therapy for Women).
Not in a simple, across-the-board way. Risk depends heavily on which hormones are used, the route of delivery, the dose, the duration, and your personal and family history. Estrogen alone (in women without a uterus) was associated with lower breast cancer rates in the WHI trial; a specific estrogen-plus-synthetic-progestin regimen was associated with higher rates. Those are two very different findings, often flattened into one myth.
Often, yes. Family history alone is not an automatic contraindication. It does mean your provider should look closely at your personal risk factors, consider whether genetic testing is appropriate, and make sure your breast screening is current before starting therapy.
Current observational research — including studies following patients for ten to fifteen years — shows a consistently reassuring safety signal, particularly when testosterone is combined with anastrozole in survivors. It’s not proof of prevention, and it requires oncology coordination and monitoring, but it’s a legitimate, evidence-informed option for carefully selected patients.
Whenever possible, the relative who had cancer should be tested first — their result is far more informative than starting with an unaffected family member, and it gives everyone in the family a clearer answer.
